期刊文献+

特发性膜性肾病合并华氏巨球蛋白血症肾损伤1例

下载PDF
导出
摘要 病例张某某,男,68岁,主因"反复双下肢水肿10年,加重5个月",2019年4月11日入院。患者2009年6月无明显诱因出现双足踝浮肿,某医院查尿常规:PRO(+++)、ERY(+++),尿蛋白定量5.36 g/24 h;Scr 78.9μmmol/L、Alb 20 g/L。临床诊断为肾病综合征。肾活检病理诊断为不典型膜性肾病,继发性肾炎待除外。予醋酸泼尼松龙50 mg、1/日,2个月后逐渐减量;环磷酰胺1000 mg、静脉滴注,前6个月每月1次,以后每3个月1次,累计总量12 g,肾病综合征完全缓解。
出处 《中国中西医结合肾病杂志》 2021年第9期830-831,共2页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献2

二级参考文献24

  • 1Swerdlow SH, Campo E, Harris NL, et al. World Health Organi- zation Classification of Tumours of Haematopoietie and Lymphoid Tissue [ M ]. 4th ed. Lyon:IARC Press, 2008:194-195.
  • 2Owen RG, Treon SP, A1-Katib A, et al. Clinicopathological definition of Waldenslrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003, 30(2): 110-115.
  • 3Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr6m' s maeroglobulinemia [J]. N Engl J Med, 2012, 367 ( 9 ) :826-833.
  • 4Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia[J]. Blood, 2009, 113 ( 18 ): 4163-4170.
  • 5Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom' s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) [J]. Leuk Res, 2010, 34 ( 10): 1340-1343.
  • 6Kastritis E, Zervas K, Repoussis P, et al. Prognostication inyoung and old patients with Waldenstr6m's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase [J]. Clin Lymphoma Myeloma, 2009, 9( 1 ): 50-52.
  • 7Treon SP. How I treat Waldenstr6m macroglobulinemia [J]. Blood, 2009, 114(12): 2375-2385.
  • 8Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreat- ed Waldenstr6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma [J]. J Clin Oncol, 2013, 31 (3): 301-307.
  • 9Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstr6m macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98) [J]. Leuk Lymphoma, 2004, 45 (10): 2047- 2055.
  • 10Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobu- linemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25(12): 1570-1575.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部